This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Amerise Biosciences posts Rs 13.91 lakh half-year loss, no revenue and cash outflow
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 1.8 pts more than its Plastic Products - Industrial peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
No operating revenue or total income was reported for the quarter and six months ended 30 September 2026. Half-year expenses of Rs 13.91 lakh led to a net loss of Rs 13.91 lakh and EPS of minus Rs 0.02, compared with a Rs 5.04 lakh loss a year earlier. The quarter loss was Rs 5.76 lakh. Operating cash flow was negative Rs 63.78 lakh, leaving cash at Rs 2.46 lakh versus Rs 59.19 lakh. Prior figures were regrouped or recast.
Widening losses, no revenue and a Rs 63.78 lakh operating cash outflow weaken sentiment, while Rs 2.46 lakh cash raises funding pressure.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹0.00 Cr | ₹0.00 Cr | unchanged |
| Operating profit | −₹0.06 Cr | −₹0.11 Cr | loss narrowed |
| Profit after tax | −₹0.06 Cr | −₹0.04 Cr | loss widened |
| EBITDA margin | — | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.